The Analjit Singh-promoted Max India Ltd has decided to sell Max Pharma, its wholly owned division, to Jubilant Organosys (formerly Vam Organic Chemicals Ltd), the largest manufacturer of specialty chemicals in the country.
Jubilant Organosys will pay Max India Rs 62.2 crore for the acquisition and will also incur transaction-related expenses of Rs 6.8 crore, bringing the entire cost of acquisition to Rs 69 crore. Jubilant intends to finance the acquisition through internal accruals and borrowings.
The boards of both Max India and Jubilant Organosys gave approval to the decision today. The acquisition is likely to be completed by November.
In the transaction, Jubilant Organosys was advised by Pricewaterhouse Coopers (PwC), while Rabo Bank represented Max India.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app